Clinical Report: Biomarkers Expand Precision in CRC

Overview

This narrative review highlights the evolving role of biomarkers in colorectal cancer (CRC) diagnosis, prognosis, and treatment selection. Established biomarkers like KRAS/NRAS and BRAF mutations, along with emerging multi-omics approaches, are shaping personalized management strategies for CRC patients.

Background

Colorectal cancer (CRC) is a leading cause of cancer incidence and mortality worldwide, necessitating advancements in diagnostic and therapeutic strategies. The integration of biomarkers into clinical practice is crucial for improving patient outcomes through personalized medicine. Understanding the complexities of tumor biology and patient-specific factors can enhance risk stratification and treatment efficacy.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Established biomarkers such as KRAS/NRAS and BRAF mutations are essential for personalized CRC management.
• Emerging biomarkers, including DNA methylation panels and circulating miRNAs, are advancing toward clinical application.
• Noninvasive assays, like stool-based DNA tests, show high sensitivity for CRC detection.
• Multi-omics integration is being explored to develop robust prognostic models for CRC.
• Liquid biopsy monitoring of ctDNA can detect resistance mutations before radiologic progression.
• Serial evaluation of biomarkers holds promise for personalizing therapy duration and sequence.

Clinical Implications

Clinicians should incorporate established and emerging biomarkers into CRC management to enhance diagnostic accuracy and treatment selection. Continuous monitoring of biomarkers can facilitate timely adjustments in therapy, improving patient outcomes.

Conclusion

The integration of biomarkers into CRC management represents a significant advancement in personalized medicine, with ongoing research needed to address existing challenges and validate new approaches.

References

1. Agüera-Sánchez A, et al., Journal of Personalized Medicine, 2023 -- Biomarkers Expand Precision in CRC
2. Evaluating the Diagnostic Utility of Genetic and Epigenetic Biomarker Panels for Colorectal Cancer: A Systematic Review, 2025
3. Three AI-Enabled Analyses Highlight Context-Dependent Biomarkers in Early-Onset Colorectal Cancer, ASCO Post, 2026
4. ASCO Treatment of Metastatic Colorectal Cancer Guideline Summary - Guideline Central, 2025
5. asco ai in oncology — Three AI-Enabled Analyses Highlight Context-Dependent Biomarkers in Early-Onset Colorectal Cancer
6. The ASCO Post — Three AI-Enabled Analyses Highlight Context-Dependent Biomarkers in Early-Onset Colorectal Cancer
7. FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
8. CIRCULATE-Japan GALAXY Confirms Effectiveness of Liquid Biopsy in Predicting Recurrence Risk and Post-operative Treatment Efficacy in Colorectal Cancer
9. ASCO Treatment of Metastatic Colorectal Cancer Guideline Summary - Guideline Central
10. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer - PubMed
11. A review on multi-omics integration for aiding study design of large scale TCGA cancer datasets | BMC Genomics | Springer Nature Link